Recombinant CSF2RA (Mavrilimumab Biosimilar) 抗体
Quick Overview for Recombinant CSF2RA (Mavrilimumab Biosimilar) 抗体 (ABIN7581350)
抗原
抗体类型
适用
宿主
克隆类型
标记
应用范围
-
-
Expression System
- CHO Cells
-
原理
- Anti-CSF2Ra / GM-CSFRa / CD116 Reference Antibody (mavrilimumab)
-
序列
- QVQLVQSGAE VKKPGASVKV SCKVSGYTLT ELSIHWVRQA PGKGLEWMGG FDPEENEIVY AQRFQGRVTM TEDTSTDTAY MELSSLRSED TAVYYCAIVG SFSPLTLGLW GQGTMVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT YTCNVDHKPS NTKVDKRVES KYGPPCPSCP APEFLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLGK,QSVLTQPPSV SGAPGQRVTI SCTGSGSNIG APYDVSWYQQ LPGTAPKLLI YHNNKRPSGV PDRFSGSKSG TSASLAITGL QAEDEADYYC ATVEAGLSGS VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV THEGSTVEKT VAPTECS
-
产品特性
- Anti-CSF2Ra / GM-CSFRa / CD116 Reference Antibody (mavrilimumab) is expressed from CHO. The heavy chain type is huIgG4SP, and the light chain type is hulambda. It has a predicted MW of 145.5 kDa.
-
纯度
- >95 %
-
亚型
- IgG4 S228P
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
说明
-
Therapeutic Agents by Target and Mechanism: CD116 inhibitors
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
浓度
- 1 mg/mL
-
缓冲液
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
储存条件
- 4 °C,-80 °C
-
储存方法
- +4°C,-80°C
-
-
- CSF2RA (Mavrilimumab Biosimilar)
-
物质类
- Biosimilar
-
分子量
- 145.5 kDa
-
UniProt
- P15509
抗原
-